• LAST PRICE
    20.7500
  • TODAY'S CHANGE (%)
    Trending Up0.2500 (1.2195%)
  • Bid / Lots
    18.8500/ 1
  • Ask / Lots
    22.7400/ 1
  • Open / Previous Close
    20.4100 / 20.5000
  • Day Range
    Low 20.3200
    High 21.0000
  • 52 Week Range
    Low 18.7200
    High 53.8800
  • Volume
    331,101
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 19, 2024

  • Nov 13, 2024

      Show headlines and story abstract
    • 4:25PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: ORKA
    • 4:25PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: ORKA

      alan.lada@orukatx.com
      ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) September 30, February 6, Assets 2024 2024 --------------- ------------- Current assets: Cash and cash equivalents $ 410,875 $ -- Subscription receivables -- 1 Prepaid expenses and other current assets 2,074 ---------- ------------- Total current assets 412,949 1 Property and equipment, net 160 -- Operating lease right-of-use assets 938 -- Other non-current assets 43 -- Total assets $ 414,090 $ 1 ========== ==== ======= Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 2,145 $ -- Accrued expenses and other current liabilities 1,710 -- Operating lease liability, current 146 -- Related party common stock warrant liability 7,681 -- Related party accounts payable and current liabilities 6,357 -- ---------- ---- ------- Total current liabilities 18,039 -- Operating lease liability, non-current 842 -- ---- ------- Total liabilities 18,881 -- ---------- ---- ------- Commitments and contingencies Preferred stock 52,841 -- Stockholders' equity: Preferred stock 2,931 -- Common stock 35 -- Additional paid-in capital 397,345 1 Accumulated deficit (57,943) -- ---------- ---- ------- Total stockholders' equity 342,368 1 Total liabilities, convertible preferred stock and stockholders' equity $ 414,090 $ 1 ========== ==== ======= ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Period from February 6, 2024 Three Months Ended (Inception) to September 30, 2024 September 30, 2024 --------------------- ----------------------- Operating expenses Research and development(1) $ 25,691 $ 49,557 General and administrative(1) 3,758 8,248 Total operating expenses 29,449 57,805 ---------------- ---------------- Loss from operations (29,449) (57,805) Other income (expense) Interest income 1,330 1,330 Interest expense (504) (1,468) ---------------- ---------------- Total other income (expense), net 826 (138) ---------------- ---------------- Net loss and comprehensive loss $ (28,623) $ (57,943) ================ ================ Net loss per share attributable to common stockholders, basic and diluted $ 1.46 $ 6.08 ================ ================ Net loss per share attributable to Series A non-voting convertible preferred Stockholders, basic and diluted $ 1,461.10 $ 6,077.25 ================ ================ Net loss per share attributable to Series B non-voting convertible preferred Stockholders, basic and diluted $ 121.76 $ 506.44 ================ ================ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,013,655 7,765,381 ================ ================ Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted 477 184 ================ ================ Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted 49,191 19,015 ================ ================ (1) Amounts include non-cash stock based compensation expense as follows (in thousands): Period from February 6, 2024 Three Months Ended (Inception) to September 30, 2024 September 30, 2024 --------------------- ----------------------- Research and development $ 7,772 $ 8,310 General and administrative 1,229 1,459 Total $ 9,001 $ 9,769 ================ ================
  • Nov 4, 2024

  • Oct 31, 2024

Peers Headlines